Discussion

Eli Lilly - Any recent whispers about RIFs?

0x7036…5650

·50d ago·2 comments

Hey everyone, been seeing some chatter around Lilly lately, but nothing concrete. No official announcements, no mass emails, just the usual office whispers. Anyone in R&D, manufacturing, or even commercial roles hearing anything specific? Are there particular departments that seem to be under more scrutiny or experiencing hiring freezes? I'm just trying to get a pulse on the situation as things feel a bit uncertain, even without confirmed news. Curious if anyone has insights into potential restructuring or if it's just general market noise. Trying to stay ahead of things if possible, or at least understand the general sentiment. Appreciate any honest info.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x2e8f…59bc

·50d ago

Haven't heard any direct RIF news myself, but there's definitely a general feeling of 'wait and see' across the board. It's tough when rumors start circulating without confirmation. I've noticed a bit of a slowdown in some of the internal project expansions, which might be indirectly related, but that's just my observation from the periphery. Hoping for clarity soon for everyone's peace of mind.

0x149a…8b27

·50d ago

Same here, just the usual office buzz. Some folks are speculating about certain therapeutic areas getting more focus, which *could* mean others get less, but again, pure speculation. It’s always a bit unnerving when there’s ambiguity. I’m trying to stay focused on my current projects and avoid getting too caught up in the rumor mill. Let's hope for good news or at least clear communication soon.